Interim Results of a Phase IIa, Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCl for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation Background
• High-dose melphalan and autologous transplantation (ASCT) is a standard procedure in transplant eligible multiple myeloma patients.
• The marketed formulation of melphalan, Alkeran, has marginal solubility and limited chemical stability upon reconstitution, i.e. use time < 60 minutes.
• Alkeran uses propylene glycol as a co-solvent, which has been reported to cause renal dysfunction, arrhythmias, hyperosmolality, metabolic acidosis, and sepsis-like syndrome.
• While Melphalan HCL for Injection (Propylene Glycol-Free), a reformulation of Alkeran for Injection, incorporates the Captisol® brand of SBECD to replace the co-solvents, and improve stability allowing longer administration durations, and potentially could enable safe administration of higher doses of melphalan, and lead to better therapeutic outcomes.
Study Design and Methods
• This is a planned interim pharmacokinetic (PK) analysis of a Phase IIa, open-label, randomized, cross-over design study after 15 (of 24) patients.
• In this study, the PK of Melphalan HCLfor Injection and Alkeran for Injection are assessed in the same MM patients undergoing an ASCT.
• The PK measures were determined using WinNonLin 6.1, and a paired difference T-test was used to determine potential differences as well as analysis of the Log-transformed systemic exposure parameters (i.e. Cmax and AUC measures) to evaluate preliminary bioequivalence.
• Furthermore, the safety and tolerability of high-dose melphalan HCL and rates of myeloablation and subsequent engraftment are determined in all patients.
• Toxicity assessed according to NCI CTCAE v3. Days to Myeloablation (n=15) 
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Conclusions for Interim Analysis
• Melphalan HCl for Injection (Propylene Glycol-Free), administered as half of a high-dose conditioning regimen, appeared to result in successful myeloablation and subsequent engraftment with no additional toxicity.
• Melphalan HCL for Injection (Propylene Glycol-Free) met the requirements for establishing bioequivalence to Alkeran for Injection, i.e. when the 90% confidence intervals for the ratio of the geometric means (Test vs Reference) were calculated, the lower and upper 90% CI of the log-transformed parameters were within the established limits of 80% to 125%. • Yet, Melphalan HCL for Injection (Propylene Glycol-Free), demonstrated a marginally greater melphalan systemic exposure (~110%) than realized from Alkeran.
• Based on these preliminary results from the Phase IIa, the follow-on study (Phase IIb) will utilize this same dosing regimen that is comparable to Alkeran. This study is designed to expose patients exclusively to the propylene glycol-free formulation and will further elaborate safety and efficacy measures for the new product.
• Melphalan HCL for Injection (Propylene Glycol-Free) also shows improved stability allowing for dosing flexibility and potentially could enable safe administration of higher doses of melphalan, and lead to better therapeutic outcomes, which may also permit reaching a wider patient population and use in a number of other lymphoma and leukemia diseased populations that indicate ASCT as treatment modality. Cancer treated with curative intent >5 years previously will be allowed.
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